ClinicalTrials.gov record
Recruiting Phase 2Phase 3 Interventional

4-aminopyridine Treatment for Nerve Injury

ClinicalTrials.gov ID: NCT03701581

Public ClinicalTrials.gov record NCT03701581. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 1:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

4-aminopyridine Treatment for Nerve Injury Resulting From Radical Retro-Pubic Prostatectomy

Study identification

NCT ID
NCT03701581
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
John Elfar
Other
Enrollment
70 participants

Conditions and interventions

Interventions

  • 4-Aminopyridine Drug
  • Placebo Other

Drug · Other

Eligibility (public fields only)

Age range
45 Years to 75 Years
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 4, 2021
Primary completion
Jun 30, 2027
Completion
Nov 30, 2028
Last update posted
Dec 16, 2025

2021 – 2028

United States locations

U.S. sites
2
U.S. states
2
U.S. cities
2
Facility City State ZIP Site status
University of Arizona Tucson Arizona 85724 Recruiting
University of Rochester Rochester New York 14602 Terminated

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03701581, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 16, 2025 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03701581 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →